Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
At the AACR Annual Meeting 2025, a session on artificial intelligence in cancer care included ways of detecting skin...
Takeaways from day three of the AACR Annual Meeting 2025 included the inspiring Opening Ceremony, a panel on cancer...
The second day of the AACR Annual Meeting 2025 included a 5K run/walk, the conclusion of the Educational Program,...
The 11 early-career researchers selected as AACR NextGen Star 2025 explain how their area of cancer research could progress...
Special programs for high school and undergraduate students at the AACR Annual Meeting provide valuable opportunities for learning, networking,...
A recently approved first-line therapy and novel insights into optimizing treatment strategies may offer new options for esophageal cancer...
A congressional forum hosted by Senators Tammy Baldwin and Peter Welch examined how NIH funding cuts could impact cancer...
Key details about the program, registration, networking opportunities, and more, to help attendees prepare for the AACR Annual Meeting...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
This month, the editors of AACR's journals tout studies showcasing the immunostimulatory impact of senescent cancer cells, a novel...